JLE

Innovations & Thérapeutiques en Oncologie

MENU

Innovation and prospects of nuclear medicine for prostate cancer Volume 5, issue 6, November-December 2019

Figures


  • Figure 1

  • Figure 2

  • Figure 3

  • Figure 4

  • Figure 5
Author
CHU de Tours
Service de médecine nucléaire
2, boulevard Tonnelle
37000 Tours
France
* Tirés à part

This article is an update of the current position and prospects of nuclear medicine for prostate cancer. Nuclear medicine plays a major role in prostate cancer imaging, in particular, in the assessment of bone extension, mainly through bone scintigraphy using 18F-Na PET, as well as investigation of biochemical recurrence using 18F-choline PET, and more recently and effectively, using 18F-fluciclovine PET and 68Ga-PSMA PET.

Nuclear medicine is currently less prominent in the treatment of prostate cancer. In supportive care, it is used as treatment for symptomatic bone metastases using 153samarium-EDMP, and as an anticancer treatment, using 223radium, for the treatment of castration-resistant prostate cancer (CRmPC) with symptomatic bone metastases. In the future, nuclear medicine is likely to play a greater therapeutic role against prostate cancer based on the use of PSMA ligands labelled with 177lutetium or 225acetinium.

Licence This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License